Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This phase II trial studies circulating cell-free tumor DNA testing to guide treatment with regorafenib or TAS-102 in patients with colorectal cancer that has spread to other areas of the body. Studying samples of blood from patients with colorectal cancer may help doctors understand how well patients respond to treatment. Regorafenib and TAS-102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known how well ctDNA testing works in guiding treatment with regorafenib and TAS-102 for patients with advanced or metastatic colorectal cancer.
DISEASE(S): Stage Ivb Colorectal Cancer Ajcc V8,Stage Ivc Colorectal Cancer Ajcc V8,Stage Iva Colorectal Cancer Ajcc V8,Stage Iv Colorectal Cancer Ajcc V8,Colorectal Neoplasms,Stage Iii Colorectal Cancer Ajcc V8,Stage Iiic Colorectal Cancer Ajcc V8,Stage Iiia Colorectal Cancer Ajcc V8,Refractory Colorectal Carcinoma,Stage Iiib Colorectal Cancer Ajcc V8
PROVIDER: 2297469 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA